GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (NAS:MNOV) » Definitions » Cash-to-Debt

MediciNova (MediciNova) Cash-to-Debt : 236.11 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is MediciNova Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MediciNova's cash to debt ratio for the quarter that ended in Dec. 2023 was 236.11.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, MediciNova could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for MediciNova's Cash-to-Debt or its related term are showing as below:

MNOV' s Cash-to-Debt Range Over the Past 10 Years
Min: 236.11   Med: No Debt   Max: No Debt
Current: 236.11

During the past 13 years, MediciNova's highest Cash to Debt Ratio was No Debt. The lowest was 236.11. And the median was No Debt.

MNOV's Cash-to-Debt is ranked better than
83.43% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs MNOV: 236.11

MediciNova Cash-to-Debt Historical Data

The historical data trend for MediciNova's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

MediciNova Cash-to-Debt Chart

MediciNova Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt 322.78 541.14 370.18 236.11

MediciNova Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 370.18 87.57 73.34 76.99 236.11

Competitive Comparison of MediciNova's Cash-to-Debt

For the Biotechnology subindustry, MediciNova's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediciNova's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediciNova's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where MediciNova's Cash-to-Debt falls into.



MediciNova Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

MediciNova's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

MediciNova's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MediciNova  (NAS:MNOV) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


MediciNova Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of MediciNova's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


MediciNova (MediciNova) Business Description

Traded in Other Exchanges
Address
4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Executives
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Hideki Nagao director 4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122
Jason J Kruger officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Douglas Paulin officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Gaeta Federico C.a. officer: Chief Scientific Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
3d Investment Partners Pte. Ltd. 10 percent owner 250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
3d Opportunity Master Fund 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Stepanow Edward C Jr. officer: Chief Financial Officer 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Kazuko Matsuda officer: Chief Medical Officer C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yuichi Iwaki director C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Carla Reyes officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Yoshio Ishizaka director 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yutaka Kobayashi director 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Geoffrey Obrien officer: Vice President 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037

MediciNova (MediciNova) Headlines

From GuruFocus